schliessen

Filtern

 

Bibliotheken

Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with hypertension 2: a 5-year, prospective, randomised, controlled trial

Is cancer related to hypertension and blood pressure? Do antihypertensive drugs promote cancer? Do antihypertensive drugs protect against cancer? We previously analysed the frequency of cardiovascular mortality and morbidity in elderly people who participated in the Swedish Trial in Old Patients wit... Full description

Journal Title: The Lancet (British edition) 2001, Vol.358 (9281), p.539-544
Main Author: LINDHOLM, Lars H
Other Authors: ANDERSON, Harald , SCHERSTEN, Bengt , WESTER, P-O , MÖLLER, Torgil R , EKBOM, Tord , HANSSON, Lennart , LANKE, Jan , DAHLÖF, Björn , DE FAIRE, Ulf , FORSEN, Kent , HEDNER, Thomas , LINJER, Erland
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: London: Lancet
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_prod_swepub_kib_ki_se_1935570
title: Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with hypertension 2: a 5-year, prospective, randomised, controlled trial
format: Article
creator:
  • LINDHOLM, Lars H
  • ANDERSON, Harald
  • SCHERSTEN, Bengt
  • WESTER, P-O
  • MÖLLER, Torgil R
  • EKBOM, Tord
  • HANSSON, Lennart
  • LANKE, Jan
  • DAHLÖF, Björn
  • DE FAIRE, Ulf
  • FORSEN, Kent
  • HEDNER, Thomas
  • LINJER, Erland
subjects:
  • Abridged Index Medicus
  • ACE inhibitors
  • Adrenergic beta blockers
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors - administration & dosage
  • Antihypertensive agents
  • Antihypertensive Agents - administration & dosage
  • Antihypertensive drugs
  • Biological and medical sciences
  • Calcium channel blockers
  • Calcium Channel Blockers - administration & dosage
  • Cancer
  • Cancer and Oncology
  • Cancer och onkologi
  • Cardiovascular system
  • Chi-Square Distribution
  • Clinical Medicine
  • Clinical trials
  • Diuretics
  • Drug therapy
  • Female
  • Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi
  • Health aspects
  • Health Sciences
  • Humans
  • Hypertension
  • Hypertension - complications
  • Hypertension - drug therapy
  • Hypertension - epidemiology
  • Hälsovetenskap
  • Incidence
  • Klinisk medicin
  • Male
  • Medical and Health Sciences
  • Medical sciences
  • Medicin och hälsovetenskap
  • Neoplasms - epidemiology
  • Neoplasms - etiology
  • Pharmacology. Drug treatments
  • Poisson Distribution
  • Prevalence
  • Prospective Studies
  • Public Health, Global Health, Social Medicine and Epidemiology
  • Registries
  • Risk
  • Risk factors
  • Sweden - epidemiology
ispartof: The Lancet (British edition), 2001, Vol.358 (9281), p.539-544
description: Is cancer related to hypertension and blood pressure? Do antihypertensive drugs promote cancer? Do antihypertensive drugs protect against cancer? We previously analysed the frequency of cardiovascular mortality and morbidity in elderly people who participated in the Swedish Trial in Old Patients with Hypertension 2 (STOP-Hypertension-2). We have also looked at the frequency of cancer in these patients. We randomly assigned 6614 elderly patients with hypertension (mean age 76 years, median time of follow-up 5.3 years) to one of three treatment strategies: conventional drugs (diuretics or b-blockers), calcium antagonists, or ACE inhibitors. We matched the patients to the Swedish Cancer Registry and compared our findings with expected values based on age, sex, and calendar-year-specific reference frequencies for the general Swedish population. We also compared the number of cancers between the three treatment groups. At baseline, 607 (9%) patients had previous malignant disease. Diagnoses were closely similar to the distribution of cancer types that might be seen in elderly patients. During follow-up, there were 625 new cases of cancer in 590 patients. The frequency of cancer did not differ significantly between the treatment strategies, including all cancers and those at individual sites. The standardised incidence ratios (SIRs) for all cancers were also close to unity: 0.92 (95% CI 0.80-1.06) for conventional drugs, 0.96 (0.83-1.10) for calcium antagonists, and 0.99 (0.86-1.13) for ACE inhibitors. No difference in cancer risk was seen between patients randomly assigned to conventional drugs, calcium antagonists, or ACE inhibitors. Thus, the general message to the practising physician is that more attention should be given to getting the blood pressure down than to the risk of cancer.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.245678
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_prod_swepub_kib_ki_se_1935570
sourceformatXML
sourcesystemPC
galeidA77374569
sourcerecordidA77374569
originalsourceidFETCH-LOGICAL-g472t-b2547169dc0d92ae165250833343fac509c8c81d8092c9a9403db47628bde3f63
addsrcrecordideNp1km-L1DAQxoso3nr6EZQgIopbTZqkaX13HP6DhRPvhHsX0mS6m7Pb1iR12Y_kt3SWW5dVlGaSMvyeZ6bTZNljRl8zyso3l5QJmpeKly8oe0mloiK_vpPNmFAil0Jd381mB-QkexDjDaVUlFTez04YkwWVhZhlP79AZ5IfetJA2gD0xIVpSVIAk9bQJ2J6R6zpLQTie7LajhAS9NH_gLhLpBWQyw04H1fkKnjT7ZIXnSOf0RX1kWx8Wh3psFLxlhgi8y2YMCdjGOIINqHhnASsNqx9BDcnduhTGLoOHHaDxg-ze63pIjzan6fZ1_fvrs4_5ouLD5_Ozxb5Uqgi5U2BH8_K2lnq6sIAK2UhacU5F7w1VtLaVrZirqJ1YWtTC8pdI1RZVI0D3pb8NFO3vnED49ToMfi1CVs9GI_vg9P7_De_Cx1Bs5pLnD8qF_9VdtOI0WDsFK3iuGyjZQ1CCwtMN01d6dZazjg3TUkZ2j2_tcOq3yeISeNkLHSd6WGYolaMCalkgeDTv8CbYQo9Dglbq-qaV9jhAVqaDrTv2yEFY3eO-kwproQsd1D-DwgfB2uPPwRaj_lj_tUR30zR9xBxi365SnFpphj_oJ_s-5yaNbjDfH7fRgSe7QETrelavA7WxyOOFbSs-C9ek_BB
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid198993819
display
typearticle
titleRelation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with hypertension 2: a 5-year, prospective, randomised, controlled trial
sourceAlma/SFX Local Collection
creatorLINDHOLM, Lars H ; ANDERSON, Harald ; SCHERSTEN, Bengt ; WESTER, P-O ; MÖLLER, Torgil R ; EKBOM, Tord ; HANSSON, Lennart ; LANKE, Jan ; DAHLÖF, Björn ; DE FAIRE, Ulf ; FORSEN, Kent ; HEDNER, Thomas ; LINJER, Erland
creatorcontribLINDHOLM, Lars H ; ANDERSON, Harald ; SCHERSTEN, Bengt ; WESTER, P-O ; MÖLLER, Torgil R ; EKBOM, Tord ; HANSSON, Lennart ; LANKE, Jan ; DAHLÖF, Björn ; DE FAIRE, Ulf ; FORSEN, Kent ; HEDNER, Thomas ; LINJER, Erland
descriptionIs cancer related to hypertension and blood pressure? Do antihypertensive drugs promote cancer? Do antihypertensive drugs protect against cancer? We previously analysed the frequency of cardiovascular mortality and morbidity in elderly people who participated in the Swedish Trial in Old Patients with Hypertension 2 (STOP-Hypertension-2). We have also looked at the frequency of cancer in these patients. We randomly assigned 6614 elderly patients with hypertension (mean age 76 years, median time of follow-up 5.3 years) to one of three treatment strategies: conventional drugs (diuretics or b-blockers), calcium antagonists, or ACE inhibitors. We matched the patients to the Swedish Cancer Registry and compared our findings with expected values based on age, sex, and calendar-year-specific reference frequencies for the general Swedish population. We also compared the number of cancers between the three treatment groups. At baseline, 607 (9%) patients had previous malignant disease. Diagnoses were closely similar to the distribution of cancer types that might be seen in elderly patients. During follow-up, there were 625 new cases of cancer in 590 patients. The frequency of cancer did not differ significantly between the treatment strategies, including all cancers and those at individual sites. The standardised incidence ratios (SIRs) for all cancers were also close to unity: 0.92 (95% CI 0.80-1.06) for conventional drugs, 0.96 (0.83-1.10) for calcium antagonists, and 0.99 (0.86-1.13) for ACE inhibitors. No difference in cancer risk was seen between patients randomly assigned to conventional drugs, calcium antagonists, or ACE inhibitors. Thus, the general message to the practising physician is that more attention should be given to getting the blood pressure down than to the risk of cancer.
identifier
0ISSN: 0140-6736
1ISSN: 1474-547X
2EISSN: 1474-547X
3DOI: 10.1016/S0140-6736(01)05704-X
4PMID: 11520524
5CODEN: LANCAO
languageeng
publisherLondon: Lancet
subjectAbridged Index Medicus ; ACE inhibitors ; Adrenergic beta blockers ; Aged ; Angiotensin-Converting Enzyme Inhibitors - administration & dosage ; Antihypertensive agents ; Antihypertensive Agents - administration & dosage ; Antihypertensive drugs ; Biological and medical sciences ; Calcium channel blockers ; Calcium Channel Blockers - administration & dosage ; Cancer ; Cancer and Oncology ; Cancer och onkologi ; Cardiovascular system ; Chi-Square Distribution ; Clinical Medicine ; Clinical trials ; Diuretics ; Drug therapy ; Female ; Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ; Health aspects ; Health Sciences ; Humans ; Hypertension ; Hypertension - complications ; Hypertension - drug therapy ; Hypertension - epidemiology ; Hälsovetenskap ; Incidence ; Klinisk medicin ; Male ; Medical and Health Sciences ; Medical sciences ; Medicin och hälsovetenskap ; Neoplasms - epidemiology ; Neoplasms - etiology ; Pharmacology. Drug treatments ; Poisson Distribution ; Prevalence ; Prospective Studies ; Public Health, Global Health, Social Medicine and Epidemiology ; Registries ; Risk ; Risk factors ; Sweden - epidemiology
ispartofThe Lancet (British edition), 2001, Vol.358 (9281), p.539-544
rights
02001 INIST-CNRS
1Copyright Lancet Ltd. Aug 18, 2001
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1112068$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11520524$$D View this record in MEDLINE/PubMed
2$$Uhttps://lup.lub.lu.se/record/1120572$$DView record from Swedish Publication Index
3$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1935570$$DView record from Swedish Publication Index
search
creatorcontrib
0LINDHOLM, Lars H
1ANDERSON, Harald
2SCHERSTEN, Bengt
3WESTER, P-O
4MÖLLER, Torgil R
5EKBOM, Tord
6HANSSON, Lennart
7LANKE, Jan
8DAHLÖF, Björn
9DE FAIRE, Ulf
10FORSEN, Kent
11HEDNER, Thomas
12LINJER, Erland
title
0Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with hypertension 2: a 5-year, prospective, randomised, controlled trial
1The Lancet (British edition)
addtitleLancet
descriptionIs cancer related to hypertension and blood pressure? Do antihypertensive drugs promote cancer? Do antihypertensive drugs protect against cancer? We previously analysed the frequency of cardiovascular mortality and morbidity in elderly people who participated in the Swedish Trial in Old Patients with Hypertension 2 (STOP-Hypertension-2). We have also looked at the frequency of cancer in these patients. We randomly assigned 6614 elderly patients with hypertension (mean age 76 years, median time of follow-up 5.3 years) to one of three treatment strategies: conventional drugs (diuretics or b-blockers), calcium antagonists, or ACE inhibitors. We matched the patients to the Swedish Cancer Registry and compared our findings with expected values based on age, sex, and calendar-year-specific reference frequencies for the general Swedish population. We also compared the number of cancers between the three treatment groups. At baseline, 607 (9%) patients had previous malignant disease. Diagnoses were closely similar to the distribution of cancer types that might be seen in elderly patients. During follow-up, there were 625 new cases of cancer in 590 patients. The frequency of cancer did not differ significantly between the treatment strategies, including all cancers and those at individual sites. The standardised incidence ratios (SIRs) for all cancers were also close to unity: 0.92 (95% CI 0.80-1.06) for conventional drugs, 0.96 (0.83-1.10) for calcium antagonists, and 0.99 (0.86-1.13) for ACE inhibitors. No difference in cancer risk was seen between patients randomly assigned to conventional drugs, calcium antagonists, or ACE inhibitors. Thus, the general message to the practising physician is that more attention should be given to getting the blood pressure down than to the risk of cancer.
subject
0Abridged Index Medicus
1ACE inhibitors
2Adrenergic beta blockers
3Aged
4Angiotensin-Converting Enzyme Inhibitors - administration & dosage
5Antihypertensive agents
6Antihypertensive Agents - administration & dosage
7Antihypertensive drugs
8Biological and medical sciences
9Calcium channel blockers
10Calcium Channel Blockers - administration & dosage
11Cancer
12Cancer and Oncology
13Cancer och onkologi
14Cardiovascular system
15Chi-Square Distribution
16Clinical Medicine
17Clinical trials
18Diuretics
19Drug therapy
20Female
21Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi
22Health aspects
23Health Sciences
24Humans
25Hypertension
26Hypertension - complications
27Hypertension - drug therapy
28Hypertension - epidemiology
29Hälsovetenskap
30Incidence
31Klinisk medicin
32Male
33Medical and Health Sciences
34Medical sciences
35Medicin och hälsovetenskap
36Neoplasms - epidemiology
37Neoplasms - etiology
38Pharmacology. Drug treatments
39Poisson Distribution
40Prevalence
41Prospective Studies
42Public Health, Global Health, Social Medicine and Epidemiology
43Registries
44Risk
45Risk factors
46Sweden - epidemiology
issn
00140-6736
11474-547X
21474-547X
fulltexttrue
rsrctypearticle
creationdate2001
recordtypearticle
recordideNp1km-L1DAQxoso3nr6EZQgIopbTZqkaX13HP6DhRPvhHsX0mS6m7Pb1iR12Y_kt3SWW5dVlGaSMvyeZ6bTZNljRl8zyso3l5QJmpeKly8oe0mloiK_vpPNmFAil0Jd381mB-QkexDjDaVUlFTez04YkwWVhZhlP79AZ5IfetJA2gD0xIVpSVIAk9bQJ2J6R6zpLQTie7LajhAS9NH_gLhLpBWQyw04H1fkKnjT7ZIXnSOf0RX1kWx8Wh3psFLxlhgi8y2YMCdjGOIINqHhnASsNqx9BDcnduhTGLoOHHaDxg-ze63pIjzan6fZ1_fvrs4_5ouLD5_Ozxb5Uqgi5U2BH8_K2lnq6sIAK2UhacU5F7w1VtLaVrZirqJ1YWtTC8pdI1RZVI0D3pb8NFO3vnED49ToMfi1CVs9GI_vg9P7_De_Cx1Bs5pLnD8qF_9VdtOI0WDsFK3iuGyjZQ1CCwtMN01d6dZazjg3TUkZ2j2_tcOq3yeISeNkLHSd6WGYolaMCalkgeDTv8CbYQo9Dglbq-qaV9jhAVqaDrTv2yEFY3eO-kwproQsd1D-DwgfB2uPPwRaj_lj_tUR30zR9xBxi365SnFpphj_oJ_s-5yaNbjDfH7fRgSe7QETrelavA7WxyOOFbSs-C9ek_BB
startdate2001
enddate2001
creator
0LINDHOLM, Lars H
1ANDERSON, Harald
2SCHERSTEN, Bengt
3WESTER, P-O
4MÖLLER, Torgil R
5EKBOM, Tord
6HANSSON, Lennart
7LANKE, Jan
8DAHLÖF, Björn
9DE FAIRE, Ulf
10FORSEN, Kent
11HEDNER, Thomas
12LINJER, Erland
general
0Lancet
1Elsevier B.V
2Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7BSHEE
80TT
90TZ
100U~
113V.
127QL
137QP
147RV
157TK
167U7
177U9
187X7
197XB
2088A
2188C
2288E
2388G
2488I
258AF
268AO
278C1
288C2
298FE
308FH
318FI
328FJ
338FK
348G5
35ABUWG
36AN0
37ASE
38AZQEC
39BBNVY
40BEC
41BENPR
42BHPHI
43C1K
44DWQXO
45FPQ
46FYUFA
47GHDGH
48GNUQQ
49GUQSH
50H94
51HCIFZ
52K6X
53K9-
54K9.
55KB0
56KB~
57LK8
58M0R
59M0S
60M0T
61M1P
62M2M
63M2O
64M2P
65M7N
66M7P
67MBDVC
68NAPCQ
69PQEST
70PQQKQ
71PQUKI
72Q9U
73S0X
747X8
75ADTPV
76AOWAS
77D95
sort
creationdate2001
titleRelation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with hypertension 2: a 5-year, prospective, randomised, controlled trial
authorLINDHOLM, Lars H ; ANDERSON, Harald ; SCHERSTEN, Bengt ; WESTER, P-O ; MÖLLER, Torgil R ; EKBOM, Tord ; HANSSON, Lennart ; LANKE, Jan ; DAHLÖF, Björn ; DE FAIRE, Ulf ; FORSEN, Kent ; HEDNER, Thomas ; LINJER, Erland
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-g472t-b2547169dc0d92ae165250833343fac509c8c81d8092c9a9403db47628bde3f63
rsrctypearticles
prefilterarticles
languageeng
creationdate2001
topic
0Abridged Index Medicus
1ACE inhibitors
2Adrenergic beta blockers
3Aged
4Angiotensin-Converting Enzyme Inhibitors - administration & dosage
5Antihypertensive agents
6Antihypertensive Agents - administration & dosage
7Antihypertensive drugs
8Biological and medical sciences
9Calcium channel blockers
10Calcium Channel Blockers - administration & dosage
11Cancer
12Cancer and Oncology
13Cancer och onkologi
14Cardiovascular system
15Chi-Square Distribution
16Clinical Medicine
17Clinical trials
18Diuretics
19Drug therapy
20Female
21Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi
22Health aspects
23Health Sciences
24Humans
25Hypertension
26Hypertension - complications
27Hypertension - drug therapy
28Hypertension - epidemiology
29Hälsovetenskap
30Incidence
31Klinisk medicin
32Male
33Medical and Health Sciences
34Medical sciences
35Medicin och hälsovetenskap
36Neoplasms - epidemiology
37Neoplasms - etiology
38Pharmacology. Drug treatments
39Poisson Distribution
40Prevalence
41Prospective Studies
42Public Health, Global Health, Social Medicine and Epidemiology
43Registries
44Risk
45Risk factors
46Sweden - epidemiology
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0LINDHOLM, Lars H
1ANDERSON, Harald
2SCHERSTEN, Bengt
3WESTER, P-O
4MÖLLER, Torgil R
5EKBOM, Tord
6HANSSON, Lennart
7LANKE, Jan
8DAHLÖF, Björn
9DE FAIRE, Ulf
10FORSEN, Kent
11HEDNER, Thomas
12LINJER, Erland
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7Academic OneFile (A&I only)
8News PRO
9Pharma and Biotech Premium PRO
10Global News & ABI/Inform Professional
11ProQuest Central (Corporate)
12Bacteriology Abstracts (Microbiology B)
13Calcium & Calcified Tissue Abstracts
14Nursing & Allied Health Database
15Neurosciences Abstracts
16Toxicology Abstracts
17Virology and AIDS Abstracts
18Health & Medical Collection
19ProQuest Central (purchase pre-March 2016)
20Biology Database (Alumni Edition)
21Healthcare Administration Database (Alumni)
22Medical Database (Alumni Edition)
23Psychology Database (Alumni)
24Science Database (Alumni Edition)
25STEM Database
26ProQuest Pharma Collection
27Public Health Database
28Lancet Titles
29ProQuest SciTech Collection
30ProQuest Natural Science Collection
31Hospital Premium Collection
32Hospital Premium Collection (Alumni Edition)
33ProQuest Central (Alumni) (purchase pre-March 2016)
34Research Library (Alumni Edition)
35ProQuest Central (Alumni Edition)
36British Nursing Database
37British Nursing Index
38ProQuest Central Essentials
39Biological Science Collection
40eLibrary
41ProQuest Central
42Natural Science Collection
43Environmental Sciences and Pollution Management
44ProQuest Central Korea
45British Nursing Index (BNI) (1985 to Present)
46Health Research Premium Collection
47Health Research Premium Collection (Alumni)
48ProQuest Central Student
49Research Library Prep
50AIDS and Cancer Research Abstracts
51SciTech Premium Collection
52British Nursing Index
53Consumer Health Database (Alumni Edition)
54ProQuest Health & Medical Complete (Alumni)
55Nursing & Allied Health Database (Alumni Edition)
56ProQuest Newsstand Professional
57ProQuest Biological Science Collection
58Consumer Health Database
59Health & Medical Collection (Alumni Edition)
60Healthcare Administration Database
61Medical Database
62Psychology Database
63Research Library
64Science Database
65Algology Mycology and Protozoology Abstracts (Microbiology C)
66Biological Science Database
67Research Library (Corporate)
68Nursing & Allied Health Premium
69ProQuest One Academic Eastern Edition
70ProQuest One Academic
71ProQuest One Academic UKI Edition
72ProQuest Central Basic
73SIRS Editorial
74MEDLINE - Academic
75SwePub
76SwePub Articles
77SWEPUB Lunds universitet
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0LINDHOLM, Lars H
1ANDERSON, Harald
2SCHERSTEN, Bengt
3WESTER, P-O
4MÖLLER, Torgil R
5EKBOM, Tord
6HANSSON, Lennart
7LANKE, Jan
8DAHLÖF, Björn
9DE FAIRE, Ulf
10FORSEN, Kent
11HEDNER, Thomas
12LINJER, Erland
formatjournal
genrearticle
ristypeJOUR
atitleRelation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with hypertension 2: a 5-year, prospective, randomised, controlled trial
jtitleThe Lancet (British edition)
addtitleLancet
date2001
risdate2001
volume358
issue9281
spage539
epage544
pages539-544
issn
00140-6736
11474-547X
eissn1474-547X
codenLANCAO
abstractIs cancer related to hypertension and blood pressure? Do antihypertensive drugs promote cancer? Do antihypertensive drugs protect against cancer? We previously analysed the frequency of cardiovascular mortality and morbidity in elderly people who participated in the Swedish Trial in Old Patients with Hypertension 2 (STOP-Hypertension-2). We have also looked at the frequency of cancer in these patients. We randomly assigned 6614 elderly patients with hypertension (mean age 76 years, median time of follow-up 5.3 years) to one of three treatment strategies: conventional drugs (diuretics or b-blockers), calcium antagonists, or ACE inhibitors. We matched the patients to the Swedish Cancer Registry and compared our findings with expected values based on age, sex, and calendar-year-specific reference frequencies for the general Swedish population. We also compared the number of cancers between the three treatment groups. At baseline, 607 (9%) patients had previous malignant disease. Diagnoses were closely similar to the distribution of cancer types that might be seen in elderly patients. During follow-up, there were 625 new cases of cancer in 590 patients. The frequency of cancer did not differ significantly between the treatment strategies, including all cancers and those at individual sites. The standardised incidence ratios (SIRs) for all cancers were also close to unity: 0.92 (95% CI 0.80-1.06) for conventional drugs, 0.96 (0.83-1.10) for calcium antagonists, and 0.99 (0.86-1.13) for ACE inhibitors. No difference in cancer risk was seen between patients randomly assigned to conventional drugs, calcium antagonists, or ACE inhibitors. Thus, the general message to the practising physician is that more attention should be given to getting the blood pressure down than to the risk of cancer.
copLondon
pubLancet
pmid11520524
doi10.1016/S0140-6736(01)05704-X